Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Ann Hematol ; 100(12): 2989-2995, 2021 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-34430990

RESUMEN

Minimal residual disease (MRD)-negative status in multiple myeloma (MM) is associated with favorable outcomes. Although EuroFlow next-generation flow (NGF) is a global standard for MRD detection, its operating cost is high. Therefore, it is desirable to develop a less expensive method with equivalent sensitivity to that of EuroFlow-NGF. In this study, we compared the analytical ability of our BML 10-color multiparameter flow cytometry (MFC) to that of EuroFlow-NGF. Bone marrow samples collected from 51 patients with MM were subjected to MRD detection using BML 10-color-MFC and EuroFlow-NGF. Our antibody panel consisted of CD38 multiepitope, CD138, CD45, CD56, CD19, CD27, CD81, CD117, cytoplasmic immunoglobulin (cIg) κ, and cIgλ in a single tube. The median percentages of total plasma cells, as per 10-color-MFC and EuroFlow-NGF, were 0.2148% and 0.2200%, respectively, with a good correlation between the methods (r = 0.950). The median percentages of myeloma cells determined via 10-color-MFC and EuroFlow-NGF were 0.0012% and 0.0007%, respectively, with a strong correlation (r = 0.954). Our 10-color-MFC demonstrated high sensitivity to detect MRD; the results showed a good correlation with those obtained using EuroFlow-NGF. Therefore, our cost-effective single-tube MFC (approximately 100 USD/sample) is a promising alternative method for the detection of MRD in patients with MM.


Asunto(s)
Citometría de Flujo/métodos , Mieloma Múltiple/diagnóstico , Neoplasia Residual/diagnóstico , Adulto , Anciano , Antígenos CD/análisis , Médula Ósea/patología , Femenino , Humanos , Inmunoglobulinas/análisis , Masculino , Persona de Mediana Edad
2.
Artículo en Inglés | MEDLINE | ID: mdl-16898418

RESUMEN

We show that the vector-derived long dsRNA specifically inhibits the replication of HCV RNA in HCV replicon. We designed a long dsRNA targeted to the full-length HCV IRES/core elements (1-to 377-nt). Our results revealed that the replication of HCV RNA was reduced to near background levels in a sequence-specific manner by the long dsRNAs in the HCV replicon. We also designed four shRNAs against several regions (120- to 139-nt, 260- to 279-nt, 330- to 349-nt, and 340- to 359-nt) of the HCV IRES/Core elements. The two HCV IRES/core-specific shRNAs, 330- to 349-nt and 340- to 359-nt, containing the AUG initiation codon sequence showed stronger HCV inhibitory effects than the other two shRNAs, 120- to 139-nt and 260- to 279-nt.


Asunto(s)
Hepacivirus/efectos de los fármacos , Hepacivirus/fisiología , ARN Bicatenario/farmacología , Replicón/efectos de los fármacos , Replicación Viral/efectos de los fármacos , Hepacivirus/genética , Pruebas de Sensibilidad Microbiana , ARN Bicatenario/síntesis química , Replicón/genética
3.
FEBS Lett ; 560(1-3): 69-74, 2004 Feb 27.
Artículo en Inglés | MEDLINE | ID: mdl-14988000

RESUMEN

DNA enzymes are RNA-cleaving single-stranded DNA molecules. We designed DNA enzymes targeting the PB2 mRNA translation initiation (AUG) region of the influenza A virus (A/PR/8/34). The modified DNA enzymes have one or two N3'-P5' phosphoramidate bonds at both the 3'- and 5'-termini of the oligonucleotides, which significantly enhanced their nuclease resistance. These modified DNA enzymes had the same cleavage activity as the unmodified DNA enzymes, determined by kinetic analyses, and reduced influenza A virus replication by more than 99%, determined by plaque formation. These DNA enzymes are highly specific; their protective effect was not observed in influenza B virus (B/Ibaraki)-infected Madin-Darby canine kidney cells.


Asunto(s)
ADN Catalítico/metabolismo , Células Epiteliales/virología , Virus de la Influenza A/metabolismo , Infecciones por Orthomyxoviridae/metabolismo , ARN Mensajero/genética , Animales , Línea Celular , ADN Catalítico/química , ADN Catalítico/genética , Perros , Virus de la Influenza A/genética , Virus de la Influenza A/crecimiento & desarrollo , Virus de la Influenza B/metabolismo , Riñón/citología , Cinética , Oligonucleótidos Antisentido/metabolismo , Especificidad de la Especie , Ensayo de Placa Viral
4.
Biochem Biophys Res Commun ; 343(2): 378-84, 2006 May 05.
Artículo en Inglés | MEDLINE | ID: mdl-16545777

RESUMEN

The baculovirus Autographa californica multiple nuclear polyhedrosis virus (AcMNPV) is used as a vector in many gene therapy studies. Wild-type AcMNPV infects many mammalian cell types in vitro, but does not replicate. We investigated the dynamics of AcMNPV genomic DNA in infected mammalian cells and used flow cytometric analysis to demonstrate that recombinant baculovirus containing a cytomegalovirus immediate early promoter/enhancer with green fluorescent protein (GFP) expressed high levels of GFP in Huh-7 cells, but not B16, Raw264.7, or YAC-1 cells. The addition of butyrate, a deacetylase inhibitor, markedly enhanced the percentage of GFP-expressing Huh-7 and B16 cells, but not Raw264.7 and YAC-1 cells. The addition of 5-aza-2'-deoxycytidine, a DNA methylation inhibitor, had no enhancing effect. Polymerase chain reaction analysis using AcMNPV-gp64-specific primers indicated that AcMNPV infected not only Huh-7 and B16 cells, but also Raw264.7 and YAC-1 cells in vitro. The genomic DNA was detected in Huh-7 and B16 cells 96 h after infection. Genomic AcMNPV DNA in YAC-1 cells was not transported to the nucleus. Luciferase assay indicated that AcMNPV p35 gene mRNA and p35 promoter activity were clearly expressed only in Huh-7 and B16 cells. These results suggest that viral genomic DNA expression is restricted by different host cell factors, such as degradation, deacetylation, and inhibition of nuclear transport, depending on the mammalian cell type.


Asunto(s)
ADN Viral/administración & dosificación , ADN Viral/genética , Células Eucariotas/virología , Nucleopoliedrovirus/genética , Transfección/métodos , Animales , Baculoviridae/genética , Femenino , Humanos , Mamíferos , Ratones , Ratones Endogámicos C57BL
5.
Biochem Biophys Res Commun ; 343(3): 988-94, 2006 May 12.
Artículo en Inglés | MEDLINE | ID: mdl-16566896

RESUMEN

RNA interference (RNAi) is a cellular process that induces gene silencing by which small duplexes of RNA specifically target a homologous sequence for cleavage by cellular ribonucleases. Here, to test the RNAi method for blocking hepatitis C virus (HCV) RNA replication, we created four short hairpin RNAs (shRNAs) targeting the HCV internal ribosome entry site/Core gene transcript using T7 RNA polymerase. shRNA suppressed the replication of HCV RNA in the HCV replicon. On the other hand, short interfering RNAs synthesized using the T7 RNA polymerase system trigger a potent induction of interferon-alpha and -beta in a variety of cells. We examined whether the shRNAs synthesized using the T7 RNA polymerase system activated double-stranded RNA-dependent protein kinase, 2'-5' oligoadenylate synthetase, or interferon-regulatory factor-3. Our results demonstrated that the T7-transcribed shRNA did not activate these proteins in Huh-7 cells and the HCV replicon. These shRNAs are a promising new strategy for anti-HCV gene therapeutics.


Asunto(s)
ARN Polimerasas Dirigidas por ADN/metabolismo , Hepacivirus/genética , Interferencia de ARN , ARN Interferente Pequeño/química , Proteínas Virales/metabolismo , Secuencia de Bases , Línea Celular Tumoral , Replicación del ADN , Endorribonucleasas/análisis , Genoma Viral , Humanos , Datos de Secuencia Molecular , Conformación de Ácido Nucleico , ARN Interferente Pequeño/biosíntesis , ARN Viral/biosíntesis , Replicón , Receptor Toll-Like 3/metabolismo , Replicación Viral , eIF-2 Quinasa/metabolismo
6.
Nucleic Acids Symp Ser (Oxf) ; (48): 307-8, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-17150601

RESUMEN

The RNA interference (RNAi) mechanism is a recently observed process in which the introduction of a double-stranded RNA (dsRNA) into a cell causes the specific degradation of an mRNA containing the same sequence. The 21-23 nt guide RNAs, generated by RNase III cleavage from longer dsRNAs, are associated with sequence-specific mRNA degradation. Here, we show that vector derived dsRNA specifically inhibit the replication of HCV RNA in HCV replicon cells. We designed a long dsRNA targeted to the full length HCV IRES region (1-377 nt). Real Time RT-PCR was performed with a TaqMan RT-PCR, to solely amplify and enable quantification of HCV RNA. Our results indicated HCV replication reduction to near background levels in a sequence-specific manner by the long-dsRNAs in the HCV replicon cells. Our results support the potential of using siRNA gene therapy to inhibit HCV replication, which may prove to be valuable in the treatment of hepatitis C.


Asunto(s)
Hepacivirus/fisiología , Interferencia de ARN , Replicación Viral , Línea Celular Tumoral , Regulación Viral de la Expresión Génica , Hepacivirus/genética , Humanos , ARN Viral/análisis , ARN Viral/genética
7.
J Immunol ; 171(3): 1133-9, 2003 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-12874198

RESUMEN

A recombinant baculovirus expressing the hemagglutinin gene of the influenza virus, A/PR/8/34 (H1N1), under the control of the chicken beta-actin promoter, was constructed. To determine the induction of protective immunity in vivo, mice were inoculated with the recombinant baculovirus by intramuscular, intradermal, i.p., and intranasal routes and then were challenged with a lethal dose of the influenza virus. Intramuscular or i.p. immunization with the recombinant baculovirus elicited higher titers of antihemagglutinin Ab than intradermal or intranasal administration. However, protection from a lethal challenge of the influenza virus was only achieved by intranasal immunization of the recombinant baculovirus. Surprisingly, sufficient protection from the lethal influenza challenge was also observed in mice inoculated intranasally with a wild-type baculovirus, as evaluated by reductions in the virus titer, inflammatory cytokine production, and pulmonary consolidations. These results indicate that intranasal inoculation with a wild-type baculovirus induces a strong innate immune response, which protects mice from a lethal challenge of influenza virus.


Asunto(s)
Gripe Humana/inmunología , Gripe Humana/prevención & control , Nucleopoliedrovirus/inmunología , Administración Intranasal , Animales , Línea Celular , Citocinas/biosíntesis , Desoxirribonucleasa I/química , Perros , Femenino , Vectores Genéticos , Glicoproteínas Hemaglutininas del Virus de la Influenza/biosíntesis , Glicoproteínas Hemaglutininas del Virus de la Influenza/genética , Glicoproteínas Hemaglutininas del Virus de la Influenza/inmunología , Calor , Humanos , Inmunidad Innata/genética , Mediadores de Inflamación/metabolismo , Virus de la Influenza A/genética , Virus de la Influenza A/inmunología , Vacunas contra la Influenza/administración & dosificación , Vacunas contra la Influenza/genética , Vacunas contra la Influenza/inmunología , Gripe Humana/mortalidad , Gripe Humana/patología , Inyecciones Intramusculares , Pulmón/inmunología , Pulmón/patología , Pulmón/virología , Activación de Macrófagos/genética , Macrófagos/inmunología , Macrófagos/metabolismo , Ratones , Ratones Endogámicos BALB C , Nucleopoliedrovirus/genética , Ribonucleasa Pancreática/química , Células Tumorales Cultivadas , Vacunas Sintéticas/administración & dosificación , Vacunas Sintéticas/genética , Vacunas Sintéticas/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA